2006
DOI: 10.1016/j.transproceed.2006.02.135
|View full text |Cite
|
Sign up to set email alerts
|

Antiviral Therapy for Hepatitis C Virus Recurrence Following Liver Transplantation: Long-Term Results From a Single Center Experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
18
0

Year Published

2006
2006
2012
2012

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(20 citation statements)
references
References 29 publications
2
18
0
Order By: Relevance
“…9,10,12 While still suboptimal, these rates of SVR are somewhat higher than those observed with the standard interferon and RBV combination therapy (ϳ20%) or those with pegylated interferon monotherapy (ϳ10%). [5][6][7] The lower rate of SVR compared to nontransplant HCV patients can be attributed to several factors including differences in the HCV dynamics between the immunocompetent and immunocompromised hosts, 20,21 higher prevalence of insulin resistance in LT recipients, and lower tolerability of PEG/RBV. 22,23 Consistent with the treatment of chronic nontransplantation HCV infection, genotypes other than 1 were associated with a significantly higher rate of SVR.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…9,10,12 While still suboptimal, these rates of SVR are somewhat higher than those observed with the standard interferon and RBV combination therapy (ϳ20%) or those with pegylated interferon monotherapy (ϳ10%). [5][6][7] The lower rate of SVR compared to nontransplant HCV patients can be attributed to several factors including differences in the HCV dynamics between the immunocompetent and immunocompromised hosts, 20,21 higher prevalence of insulin resistance in LT recipients, and lower tolerability of PEG/RBV. 22,23 Consistent with the treatment of chronic nontransplantation HCV infection, genotypes other than 1 were associated with a significantly higher rate of SVR.…”
Section: Discussionmentioning
confidence: 99%
“…[5][6][7] The introduction of pegylated interferon alfa (PEG) therapy in combination with RBV therapy (PEG/RBV) significantly improved the antiviral response rate in chronic HCV patients, although data from liver transplant recipients is limited. To date, there have been 10 published studies that enrolled greater than 20 patients each to evaluate the efficacy and safety of PEG/RBV combination therapy in LT patients with reported SVR rates ranging between 31% and 45%.…”
mentioning
confidence: 99%
“…They are responsible for the intracellular RNA-degradation and the inhibition of RNA-translation. Among all known interferons (IFN-α, IFN-β, Peg-IFN-α2b), pegylated IFN-α2a seems to have the highest antiviral potency, though similar to Peg-IFN-α2b, demonstrating superior treatment results in patients with HCV-re-infection [19,[70][71][72][73][74][75]. Attenuation of renal clearance and improved biochemical stability may explain prolonged half-time and therapeutical advantages observed.…”
Section: Antiviral Therapymentioning
confidence: 99%
“…In the sole randomized controlled trial of standard IFN and RBV for histologic recurrent HCV, SVR was 21% after 48 weeks, but there was no difference in histology [23••]. Several noncontrolled trials of IFN plus RBV show SVR from 12.5% to 30.0% [24][25][26][27][28][29][30]. The combination of PEG-IFN and RBV may yield SVR in 21% to 45%, with improvements in inflammatory grade and fibrosis stage [31][32][33][34], although 20% to 32% discontinue therapy.…”
Section: Post-transplantation Recurrent Hcv Treatmentmentioning
confidence: 99%